Introduction
Chronic GVHD (cGVHD) is a major cause of transplantrelated morbidity and mortality in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-SCT). 1 The syndrome has features resembling autoimmune disorders and affects a wide spectrum of organs, resulting in manifestations such as oral mucositis, dry eyes and a scleroderma-like skin disease. [2] [3] [4] Liver injury, which affects patient prognosis, is also common after allo-SCT. Chronic liver GVHD is one of the most serious problems related to long-term survival. It is characterized by the destruction of bile duct epithelium followed by progressive cholestasis, with elevations in serum alkaline phosphatase (ALP), g-glutamyl transpeptidase (g-GTP) and serum bilirubin levels; 5, 6 it resembles primary biliary cirrhosis (PBC) clinically and histologically. [7] [8] [9] Ursodeoxycholic acid (UDCA), which is widely accepted as the standard medical treatment with documented efficacy, 10 is also used for the treatment of cGVHD of the liver, along with corticosteroids and calcineurin inhibitors. 11 Although UDCA has been reported to reduce hepatic complications after allo-SCT and improve survival, there are still a considerable number of patients with cGVHD who are resistant to UDCA. 4 Bezafibrate (BF), which is a widely used agent for hyperlipidemia, has been used in the treatment of PBC patients. 12, 13 Several reports have indicated that BF improved hepatobiliary enzyme levels, even in UDCAresistant PBC patients. [13] [14] [15] Therefore, these findings prompted us to study the biochemical efficacy of BF on the hepatic manifestations of cGVHD by reviewing patients who had been given BF for their persistently high hepatobiliary enzyme levels after allo-SCT.
Materials and methods
This study was a retrospective analysis of the efficacy of BF for hepatic cGVHD after allo-SCT. Of 124 patients who survived 100 days or more after allo-SCT between January 2001 and December 2007 at Kumamoto Medical Center, 87 (70.1%) developed cGVHD (extensive, 39; limited, 48). Although the diagnosis of cGVHD for each patient was made according to the historical definition, 2 all of them were reassessed on the basis of National Institute of Health (NIH) criteria issued in 2006. Hepatic involvement of cGVHD was diagnosed either by liver biopsy or by simultaneous clinical and laboratory parameters. Patients with hepatic cGVHD meeting the following criteria were entered into this study: ALP or g-GTP elevated more than twice the upper normal limits and improved less than 10% by UDCA and immunosuppressants (PSL and/or CsA); negative for anti-hepatitis C virus antibody, hepatitis B virus surface antigen and CMV antigen; no evidence of non-alcoholic fatty liver disease and other biliary tract diseases on ultrasonography and/or computerized tomography (CT). Furthermore, 12 patients (non-BF group) treated without BF from 1997 to 2000 in our hospital were selected retrospectively so that they were age and sex matched with the BF group (Table 1, patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
Bezafibrate was given orally 400 mg b.i.d. a day for at least 4 weeks after normalization or reaching the plateau level of hepatobiliary enzymes. Itraconazole (200 mg) and famotidine (20 mg) were given while the patients were treated with prednisolone. Biochemical analyses included aspartate aminotransferase (AST), alanine amino transferase (ALT), ALP and g-GTP levels, and the patients' clinical symptoms were evaluated monthly. The study was approved by the local ethics committee, and written informed consent was obtained from each patient included in the study.
Statistics
Laboratory data after BF administration were compared with those before treatment using the nonparametric Mann-Whitney test or the Wilcoxon matched-pairs single rank test, as appropriate. All analyses were two tailed, and P-values o0.05 were considered statistically significant.
Results
Eight patients (three men, five women; age range, 28-57 years) met the above criteria and were given BF for hepatic cGVHD. The patients' characteristics are summarized in Table 1 . The conditioning regimen consisted of BU/CY for five patients, TBI/CY for one patient and fludarabine/BU for two patients. All but one patient received a fully matched sibling donor transplant. Only two patients experienced acute GVHD; however, a subtype of cGVHD was seen in all patients. Their diagnoses of cGVHD were reevaluated using the NIH criteria 6 based on the presence of diagnostic clinical signs on the skin (patients 1, 2, 4 and 6) or mouth (patient 5), or distinctive skin manifestations (patients 7 and 8) confirmed by biopsy. Patient 3 was diagnosed as having cGVHD based on the presence of bronchiolitis obliterans, which was confirmed with pulmonary function testing and chest CT ( Table 2) . Global scoring was also performed using the NIH criteria. 6 The diagnosis of liver cGVHD was made on the bases of liver biopsy in patients 1 and 5 and simultaneous clinical and laboratory parameters compatible with liver GVHD in the other patients (Patients 2, 3, 4, 6, 7 and 8).
Effects of BF on liver cGVHD
Four patients were treated with PSL without satisfactory efficacy for sustained elevations of ALP and g-GTP. In two patients with severe cGVHD, BF was given before PSL for 
the liver cGVHD, because we were already aware of the beneficial effect of BF. In patients 7 and 8, PSL was not given because their cGVHD symptoms were not severe. The median time of BF initiation was 267 days (range, 154-554 days) after transplantation. The effects of BF on serum liver and biliary enzyme levels and blood biochemistry are shown in Table 3 and Figure 1 . The mean serum ALP and g-GTP levels were significantly decreased within 1 month after the start of BF therapy (ALP, 964.9.0±306.9 to 597.8±102.5 IU/l, P ¼ 0.012; g-GTP, 528.8 ± 299.0 to 269.0 ± 119.9 IU/l, P ¼ 0.012), and further improvement was observed until 16 weeks. Complete normalization of hepatobiliary enzymes was observed in two patients. The AST and ALT levels remained almost unchanged after 1 month on BF therapy, but decreased significantly at 16 weeks. Although the duration of administration differed considerably from case to case (median, 57 weeks; range, 20-202 weeks), BF maintained improvement or normalization of biliary enzymes and transaminases during the time it was being taken. No side effects of BF, such as dizziness, muscle pain or renal dysfunction, were observed in this study.
On the other hand, no significant improvement was seen in the non-BF group (Figure 2 ).
Case reports
The clinical courses of all patients are shown in Figure 1 .
The serum ALP and g-GTP levels of patient 1 were elevated around 6 months after transplantation (Figure 1a) . Nine months after transplantation, the serum bilirubin level also increased, accompanied by dry eyes and oral mucositis with salivary gland damage. After confirmation of cGVHD histologically by liver biopsy, PSL 30 mg (0.5 mg/kg) was given. Liver enzyme and bilirubin levels began to decrease immediately after PSL therapy; however, ALP and g-GTP levels remained high and became exacerbated again 2 months after the addition of PSL. BF was started, and the patient showed rapid improvement of biliary enzyme levels soon after the start of treatment. Although the liver enzymes (AST and ALT) increased temporarily after a respiratory infection (21 months), the levels normalized subsequently. Little improvement was seen in the skin, mouth and eye lesions of cGVHD.
Patient 4 had been treated with PSL for grade II acute GVHD 2 months after SCT (Figure 1d ). The patient recovered from acute GVHD; however, serum ALP and g-GTP levels remained high 4 months after transplantation, even though the patient had been taking UDCA, CsA and PSL. Five months after transplantation, BF was given for sustained biliary enzyme elevations. Although serum ALP and g-GTP levels improved immediately, the patient decided to discontinue BF after 6 weeks because of oral mucositis due to cGVHD. Serum ALP and g-GTP levels of the patient increased again after stopping BF, but after the reintroduction of BF, they gradually improved again. No improvement was seen in the skin, mouth and eye lesions of cGVHD.
In patient 7, serum ALP and g-GTP levels were elevated 4 months after transplantation, though the patient had been taking UDCA and CsA without any dose reduction (Figure 1g ). Five months after transplantation, elevated Bezafibrate in hepatic cGVHD M Hidaka et al serum AST and ALT levels were accompanied by skin lesions that indicated cGVHD. After BF was given for hepatic cGVHD, serum ALP, g-GTP, AST and ALT levels of the patient improved immediately and have been maintained within normal ranges for more than 2 years up to the present without significant improvement in the skin lesions of cGVHD.
Discussion cGVHD is the most common non-relapse complication after allo-SCT. Although GVHD is associated with a potent antileukemic effect, cGVHD is also associated with significant morbidity and treatment-related mortality. cGVHD affects many organs and tissues, such as the skin, A combination of CsA and PSL has been recommended for the standard initial treatment of cGVHD; however, long-term immunosuppressive therapy may lead to lifethreatening infections or relapse of underlying hematological malignancy. Even in patients who respond to this initial immunosuppression therapy, recurrence of cGVHD is frequent, and re-treatment is required to control this complication. In PSL-resistant cases, management of cGVHD is not well defined. Therefore, a new therapeutic approach is greatly needed.
A recent report of a large, randomized, multicenter trial revealed that prophylactic UDCA administration was effective in preventing severe acute GVHD after allo-SCT and improved survival, 11 but there was no difference in cGVHD. Chronic nonsuppurative destructive cholangitis is a common pathological feature of cGVHD and PBC, 16 where the bile duct epithelial cells are the targets of immunological injury. The clinical manifestations of cGVHD of the liver also resemble those of PBC, which have been characterized by progressive cholestasis accompanied by increased ALP, g-GTP and bilirubin levels. UDCA is the only approved drug for PBC, and several reports indicate that UDCA slows the progression of the disease and may prolong survival when given in the early stage of the disease. 10 Recently, several groups reported that BF, an antihyperlipidemic agent, has a beneficial effect on the treatment of PBC patients who fail to respond to UDCA. 14, 15 Therefore, we analyzed the efficacy of BF in allo-SCT patients with liver cGVHD. BF significantly lowered the serum liver and biliary enzyme levels in all patients with liver cGVHD who showed a suboptimal response to UDCA and immunosuppressants (Table 3 ; Figures 1f-h) . BF improved the hepatobiliary enzyme levels even after corticosteroid therapy in some patients (Figures 1a-e) , suggesting that BF exerts a unique effect on intrahepatic cholestasis.
BF has an anti-inflammatory activity on the intrahepatic bile duct through its receptor, peroxisomal proliferatoractivated receptor (PPAR)-a. Activation of PPAR-a Table 1 ). Their liver cGVHD was treated conventionally, including PSL and/or ursodeoxycholic acid (UDCA) without BF. The data are shown as medians (boxes) and standard deviations (bars).
